| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website https://www.jocmr.org |
Original Article
Volume 14, Number 9, September 2022, pages 335-340
The Outcome of Tapered Steroid Regimen When Used to Treat Acute Borderline Cellular Rejection After Kidney Transplant: A Single-Center Experience
Tables
| NRG (N = 63) | RG (N = 28) | P-value | |
|---|---|---|---|
| NRG: non-responder group; RG: responder group; Q1: first interquartile range; Q3: third interquartile range. | |||
| Age (years) | 0.40 | ||
| Missing | 0 | 0 | |
| Median (Q1, Q3) | 59.0 (47.0, 68.0) | 61.5 (50.2, 71.2) | |
| Gender | 0.36 | ||
| Missing | 0 | 0 | |
| Female | 26 (41.3%) | 15 (53.6%) | |
| Race | 0.50 | ||
| Missing | 0 | 0 | |
| Non-Hispanic White | 37 (58.7%) | 16 (57.1%) | |
| Non-Hispanic Black | 22 (34.9%) | 8 (28.6%) | |
| Hispanic White | 1 (1.6%) | 2 (7.1%) | |
| Other | 3 (4.8%) | 2 (7.1%) | |
| NRG (N = 63) | RG (N = 28) | P-value | |
|---|---|---|---|
| BCR: borderline cellular rejection; cPRA: calculated panel reactive antibodies; NRG: non-responder group; RG: responder group; Q1: first interquartile range; Q3: third interquartile range. | |||
| Hypertension | 0.79 | ||
| Missing | 9 | 1 | |
| No | 40 (74.1%) | 19 (70.4%) | |
| Yes | 14 (25.9%) | 8 (29.6%) | |
| Diabetes mellitus | 0.63 | ||
| Missing | 9 | 1 | |
| No | 35 (64.8%) | 16 (59.3%) | |
| Yes | 19 (35.2%) | 11 (40.7%) | |
| Donor type | 0.43 | ||
| Missing | 0 | 0 | |
| Living donor | 17 (27.0%) | 5 (17.9%) | |
| Deceased donor | 46 (73.0%) | 23 (82.1%) | |
| Induction agent | 0.74 | ||
| Missing | 1 | 0 | |
| Alemtuzumab | 22 (35.5%) | 9 (32.1%) | |
| Basiliximab | 15 (24.2%) | 9 (32.1%) | |
| Thymoglobulin | 25 (40.3%) | 10 (35.7%) | |
| Class I cPRA | 0.64 | ||
| Missing | 11 | 7 | |
| Median (Q1, Q3) | 1.5 (0.0, 32.0) | 10.0 (0.0, 48.0) | |
| Class II cPRA | 0.29 | ||
| Missing | 11 | 7 | |
| Median (Q1, Q3) | 0.0 (0.0, 37.0) | 0.0 (0.0, 56.0) | |
| Time from transplant to first diagnosed acute BCR (in months) | 0.21 | ||
| Missing | 0 | 0 | |
| Median (Q1, Q3) | 12.3 (4.3, 25.2) | 17.5 (10.9, 47.9) | |
| Time between biopsies (in months) | 0.78 | ||
| Missing | 0 | 0 | |
| Median (Q1, Q3) | 2.7 (1.6, 3.7) | 2.5 (2.0, 3.5) | |
| NRG (N = 70) | RG (N = 39) | P-value | |
|---|---|---|---|
| NRG: non-responder group; RG: responder group; Q1: first interquartile range; Q3: third interquartile range; SCr: serum creatinine; P: plasmatic. | |||
| Initial SCr | 0.36 | ||
| Median (Q1, Q3) | 1.6 (1.2, 2.1) | 1.5 (1.4, 2.4) | |
| 1-month post-biopsy SCr | 0.44 | ||
| Median (Q1, Q3) | 1.5 (1.2, 2.0) | 1.5 (1.2, 2.1) | |
| 2-month post-biopsy SCr | 0.099 | ||
| Median (Q1, Q3) | 1.4 (1.1, 1.9) | 1.7 (1.3, 2.1) | |
| 3-month post-biopsy SCr | 0.94 | ||
| Median (Q1, Q3) | 1.5 (1.2, 1.7) | 1.3 (1.1, 1.8) | |
| 6-month post-biopsy SCr | 0.23 | ||
| Median (Q1, Q3) | 1.4 (1.1, 1.8) | 1.6 (1.4, 1.9) | |
| 12-month post-biopsy SCr | 0.92 | ||
| Median (Q1, Q3) | 1.5 (1.2, 1.8) | 1.5 (1.2, 1.6) | |
| Initial urine P/Cr | 0.16 | ||
| Missing | 6 | 0 | |
| Median (Q1, Q3) | 0.1 (0.1, 0.3) | 0.2 (0.1, 0.3) | |
| Follow-up urine P/Cr | 0.55 | ||
| Missing | 16 | 4 | |
| Median (Q1, Q3) | 0.1 (0.1, 0.3) | 0.2 (0.1, 0.3) | |
| Initial tacrolimus level | 0.44 | ||
| Missing | 8 | 1 | |
| Median (Q1, Q3) | 7.0 (5.8, 8.2) | 7.2 (6.1, 9.0) | |
| Follow-up tacrolimus level | 0.60 | ||
| Missing | 9 | 1 | |
| Median (Q1, Q3) | 8.3 (7.0, 10.2) | 8.1 (7.0, 9.3) | |